RIS Rx Announces Growth Investment from Summit Partners to Combat Revenue Leakage in Pharma Patient Affordability Programs
Summary
RIS Rx announced a growth investment from Summit Partners to expand its platform for reducing revenue leakage in pharmaceutical patient affordability programs. The company uses proprietary software, automation, and real-time analytics to identify and prevent gross-to-net leakage for drug manufacturers. RIS Rx says its products help patient assistance programs reach intended recipients and improve affordability and access. The new capital will support product development, team growth, and expanded client services.
Funding
Amount
-
Total raised
Date
June 16, 2025
Announcement date
Investors
Jamieson Corporate Finance, Morgan Stanley Principal Investments, Latham & Watkins, Summit Partners, DLA Piper
Lead investors
Company
https://www.risrx.com
Funded company
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
SaaS
Healthcare Software
Revenue Management Software
Linked Companies
RIS Rx
$10M to $25M